艾伯维斥资3.8亿美元在芝加哥建设肥胖与神经科学原料药设施。
AbbVie budgets $380M for obesity and neuroscience API facilities in Chicago
生命科学资讯
生物技术与制药领域的最新动态
前沿与港湾分别与葛兰素史克、Solstice达成许可协议
Frontier, Harbour do licensing deals with GSK, Solstice
联邦实验为数字健康开辟新市场——前提是成功
A federal experiment opens up a new market for digital health — if it works
罗氏将停止针对杜氏肌营养不良症的骨骼健康治疗研究。
Roche to stop work on bone health treatment for Duchenne
罗氏将停止针对杜氏肌营养不良症的骨健康治疗研究——终点新闻
Roche to stop work on bone health treatment for Duchenne - Endpoints News
默克重组；黑石集团将为强生药物试验提供资金。
Merck reorganizes; Blackstone to fund trials for J&J drug
罕见自闭症基因疗法首次进入临床试验阶段
First test of gene therapy for rare form of autism is underway
吉利德将以78亿美元收购细胞疗法合作伙伴Arcellx。
Gilead to acquire cell therapy partner Arcellx for $7.8B
诺和诺德CagriSema在头对头肥胖试验中不敌礼来Zepbound。
Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial
MoonLake在FDA提交前充满"信心"，披露中期关节炎试验成功
MoonLake has 'confidence' ahead of FDA submission, discloses mid-stage arthritis win
潜在Eylea竞争对手令人失望；FDA将审查Moderna流感疫苗；又一罕见病疗法遭拒；及其他动态。
Potential Eylea competitor disappoints; FDA to review Moderna’s flu vaccine; Another rare disease rejection; and more
万达制药获FDA批准推出“扩展产品线”抗精神病药物。
Vanda gets FDA approval for ‘franchise-extending’ antipsychotic
Grail癌症检测在英国研究后面临新不确定性
Grail's cancer test faces new uncertainty after UK study
Ionis终止针对唐氏综合症患者的阿尔茨海默病药物研发。
Ionis scraps Alzheimer’s drug for people with Down syndrome
最高法院关税裁决维持特朗普针对制药业的权力
Supreme Court tariff ruling lets stand Trump’s authority to target pharma
坎德尔价格发行，签署特许权协议；Calquence标签扩展。
Candel prices offering, signs royalty deal; Calquence label expands
第一三共任命蔡约翰领导研发，竹下健离职。
Daiichi taps John Tsai to lead R&D as Ken Takeshita departs
诺华将以1.59亿美元向私募股权财团出售印度子公司。
Novartis to divest India unit to private equity-led consortium for $159M
赛诺菲任命专科护理负责人；百健董事长将于六月退休
Sanofi appoints specialty care head; Biogen chair to retire in June
Grail癌症检测在英国研究中未达主要研究目标
Grail's cancer test misses primary study goal in UK study